Literature DB >> 31092010

Albuminuria, the High-Density Lipoprotein Proteome, and Coronary Artery Calcification in Type 1 Diabetes Mellitus.

Baohai Shao1, Leila R Zelnick1, Jake Wimberger1, Jonathan Himmelfarb1, John Brunzell1, W Sean Davidson2, Janet K Snell-Bergeon3, Karin E Bornfeldt1, Ian H de Boer1, Jay W Heinecke1.   

Abstract

Objective- Albuminuria is an important risk factor for cardiovascular disease in diabetes mellitus. We determined whether albuminuria associates with alterations in the proteome of HDL (high-density lipoprotein) of subjects with type 1 diabetes mellitus and whether those alterations associated with coronary artery calcification. Approach and Results- In a cross-sectional study of 191 subjects enrolled in the DCCT (Diabetes Control and Complications Trial)/EDIC study (Epidemiology of Diabetes Interventions and Complications), we used isotope dilution tandem mass spectrometry to quantify 46 proteins in HDL. Stringent statistical analysis demonstrated that 8 proteins associated with albuminuria. Two of those proteins, AMBP (α1-microglobulin/bikunin precursor) and PTGDS (prostaglandin-H2 D-isomerase), strongly and positively associated with the albumin excretion rate ( P<10-6). Furthermore, PON (paraoxonase) 1 and PON3 levels in HDL strongly and negatively associated with the presence of coronary artery calcium, with odds ratios per 1-SD difference of 0.63 (95% CI, 0.43-0.92; P=0.018) for PON1 and 0.59 (95% CI, 0.40-0.87; P=0.0079) for PON3. Only 1 protein, PON1, associated with both albumin excretion rate and coronary artery calcification. Conclusions- Our observations indicate that the HDL proteome is remodeled in type 1 diabetes mellitus subjects with albuminuria. Moreover, low concentrations of the antiatherosclerotic protein PON1 in HDL associated with both albuminuria and coronary artery calcification, raising the possibility that alterations in HDL protein cargo mediate, in part, the known association of albuminuria with cardiovascular risk in type 1 diabetes mellitus. Visual Overview- An online visual overview is available for this article.

Entities:  

Keywords:  albuminuria; atherosclerosis; kidney diseases; lipoproteins; proteomics; triglycerides

Mesh:

Substances:

Year:  2019        PMID: 31092010      PMCID: PMC6594860          DOI: 10.1161/ATVBAHA.119.312556

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  56 in total

1.  Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population.

Authors:  Hans L Hillege; Vaclav Fidler; Gilles F H Diercks; Wiek H van Gilst; Dick de Zeeuw; Dirk J van Veldhuisen; Rijk O B Gans; Wilbert M T Janssen; Diederick E Grobbee; Paul E de Jong
Journal:  Circulation       Date:  2002-10-01       Impact factor: 29.690

2.  Serum amyloid A in uremic HDL promotes inflammation.

Authors:  Thomas Weichhart; Chantal Kopecky; Markus Kubicek; Michael Haidinger; Dominik Döller; Karl Katholnig; Cacang Suarna; Philipp Eller; Markus Tölle; Christopher Gerner; Gerhard J Zlabinger; Markus van der Giet; Walter H Hörl; Roland Stocker; Marcus D Säemann
Journal:  J Am Soc Nephrol       Date:  2012-01-26       Impact factor: 10.121

3.  The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis?

Authors:  Daniel J Rader; Alan R Tall
Journal:  Nat Med       Date:  2012-09       Impact factor: 53.440

4.  Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis.

Authors:  D M Shih; Y R Xia; X P Wang; E Miller; L W Castellani; G Subbanagounder; H Cheroutre; K F Faull; J A Berliner; J L Witztum; A J Lusis
Journal:  J Biol Chem       Date:  2000-06-09       Impact factor: 5.157

5.  CETP Inhibitors - A New Inning?

Authors:  Robert A Hegele
Journal:  N Engl J Med       Date:  2017-09-28       Impact factor: 91.245

6.  Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.

Authors:  H C Gerstein; J F Mann; Q Yi; B Zinman; S F Dinneen; B Hoogwerf; J P Hallé; J Young; A Rashkow; C Joyce; S Nawaz; S Yusuf
Journal:  JAMA       Date:  2001-07-25       Impact factor: 56.272

7.  A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism.

Authors:  A Rigotti; B L Trigatti; M Penman; H Rayburn; J Herz; M Krieger
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-11       Impact factor: 11.205

8.  The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study.

Authors:  Patricia A Cleary; Trevor J Orchard; Saul Genuth; Nathan D Wong; Robert Detrano; Jye-Yu C Backlund; Bernard Zinman; Alan Jacobson; Wanjie Sun; John M Lachin; David M Nathan
Journal:  Diabetes       Date:  2006-12       Impact factor: 9.461

9.  Spectrum and prevalence of atherogenic risk factors in 27,358 children, adolescents, and young adults with type 1 diabetes: cross-sectional data from the German diabetes documentation and quality management system (DPV).

Authors:  K Otfried Schwab; Jürgen Doerfer; Wolfgang Hecker; Jürgen Grulich-Henn; Dagobert Wiemann; Olga Kordonouri; Peter Beyer; Reinhard W Holl
Journal:  Diabetes Care       Date:  2006-02       Impact factor: 19.112

10.  Optimized bacterial expression of human apolipoprotein A-I.

Authors:  Robert O Ryan; Trudy M Forte; Michael N Oda
Journal:  Protein Expr Purif       Date:  2003-01       Impact factor: 1.650

View more
  7 in total

1.  High Concentration of Medium-Sized HDL Particles and Enrichment in HDL Paraoxonase 1 Associate With Protection From Vascular Complications in People With Long-standing Type 1 Diabetes.

Authors:  Tomas Vaisar; Jenny E Kanter; Jake Wimberger; Angela D Irwin; John Gauthier; Emily Wolfson; Vanessa Bahnam; I-Hsien Wu; Hetal Shah; Hillary A Keenan; Carla J Greenbaum; George L King; Jay W Heinecke; Karin E Bornfeldt
Journal:  Diabetes Care       Date:  2019-10-09       Impact factor: 19.112

2.  HDL and ASCVD.

Authors:  Hongtu Cui; Qian Du
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

3.  An Increased Plasma Level of ApoCIII-Rich Electronegative High-Density Lipoprotein May Contribute to Cognitive Impairment in Alzheimer's Disease.

Authors:  Hua-Chen Chan; Liang-Yin Ke; Hsiao-Ting Lu; Shih-Feng Weng; Hsiu-Chuan Chan; Shi-Hui Law; I-Ling Lin; Chuan-Fa Chang; Ye-Hsu Lu; Chu-Huang Chen; Chih-Sheng Chu
Journal:  Biomedicines       Date:  2020-11-26

4.  Pulmonary surfactant protein B carried by HDL predicts incident CVD in patients with type 1 diabetes.

Authors:  Baohai Shao; Janet K Snell-Bergeon; Laura L Pyle; Katie E Thomas; Ian H de Boer; Vishal Kothari; Jere Segrest; William S Davidson; Karin E Bornfeldt; Jay W Heinecke
Journal:  J Lipid Res       Date:  2022-03-14       Impact factor: 6.676

5.  The landscape of immune cell infiltration in the glomerulus of diabetic nephropathy: evidence based on bioinformatics.

Authors:  Wei Zhou; Yaoyu Liu; Qinghong Hu; Jiuyao Zhou; Hua Lin
Journal:  BMC Nephrol       Date:  2022-09-05       Impact factor: 2.585

Review 6.  Subpopulations of High-Density Lipoprotein: Friends or Foes in Cardiovascular Disease Risk in Chronic Kidney Disease?

Authors:  Susana Coimbra; Flávio Reis; Maria João Valente; Susana Rocha; Cristina Catarino; Petronila Rocha-Pereira; Maria Sameiro-Faria; Elsa Bronze-da-Rocha; Luís Belo; Alice Santos-Silva
Journal:  Biomedicines       Date:  2021-05-16

7.  Enrichment of apolipoprotein A-IV and apolipoprotein D in the HDL proteome is associated with HDL functions in diabetic kidney disease without dialysis.

Authors:  Monique F M Santana; Aécio L A Lira; Raphael S Pinto; Carlos A Minanni; Amanda R M Silva; Maria I B A C Sawada; Edna R Nakandakare; Maria L C Correa-Giannella; Marcia S Queiroz; Graziella E Ronsein; Marisa Passarelli
Journal:  Lipids Health Dis       Date:  2020-09-14       Impact factor: 3.876

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.